

17. (Amended) The method of claim 2 wherein the [source of carbohydrate nutrients] carbohydrate is a hexose, pentose, hexose alcohol, pentose alcohol, or any combination thereof.
18. (Amended) The method of claim [3] 2 wherein the [source of carbohydrate nutrients] carbohydrate is a glucose, fructose, galactose, xylitol, mannitol, sorbitol, or any combination thereof.
- B2 19. (Amended) The method of claim 1 wherein [the source of carbohydrate nutrients] said nutrient is one or more [assimilable] amino acids, lipids, free fatty acids, mono- or diglycerides or glycerol or any combination thereof.
- Sub E1 20. (Amended) The method of claim [2] 1 wherein the administration of the [source of carbohydrate nutrients] nutrient to the patient produces a blood glucose level in the patient of [no more than] from about 80 to 180 mg glucose per deciliter of blood and the rate of administration of the source of carbohydrate nutrients is calculated to deliver up to about 1000 g of glucose or its equivalent per patient per day.
- Sub C1 21. (Amended) The method of claim 1 wherein the administration of the insulinotropic peptide or peptides produces a blood level of the peptides in the range of 1 pmol per L to 1 [mmol] nmol per L of blood plasma.
- B2 23. (Amended) The method of claim [2] 1 wherein [the nutrient composition comprises a source of carbohydrate] said nutrient is in a first aqueous medium and said one or more insulinotropic peptides is in a second aqueous medium or a pharmaceutically acceptable solid or gel tab or sustained release matrix.
24. (Amended) The method of claim 1 wherein [the standardized concentration of insulinotropic peptide or peptides being administered is] said insulinotropic peptide

or peptides are administered at a standardized concentration sufficient to provide a plateau level of the insulinotropic peptide or peptides in the patient's blood.


25. (Amended) The method of claim 1 wherein the nutrient[s] and insulinotropic peptide or peptides are continuously [and coterminally] administered.


B3
cont
26. (Amended) A nutrient composition comprising [a source of carbohydrate nutrients and] one or more insulinotropic peptides [in an amount calculated to provide a standardized concentration of insulinotropic peptide or peptides when administered to a patient, wherein the nutrients and peptide or peptides are in separate or combined form] and as nutrients (1) a carbohydrate, (2) an amino acid, and (3) a lipid, free fatty acid, monoglyceride, diglycerides, or glycerol, wherein the nutrients and insulinotropic peptide or peptides are in separate or combined form.

B4
28. (Amended) The nutrient composition of claim [27] 26 wherein [the source of carbohydrate nutrient] the carbohydrate is present at a concentration of about 2% to about 50% by weight of glucose or its equivalent per L.

30. (Amended) The nutrient composition of claim 26 wherein the [standardized concentration of] insulinotropic peptide or peptides is in a standardized concentration sufficient to provide a plateau level of the insulinotropic peptide or peptides in the patient's blood.

B5
31. (Amended) [A nutrient composition comprising a kit containing a first aqueous mixture of a source of carbohydrate nutrients] A kit comprising the nutrient composition of claim 26, wherein said nutrients are contained in a first aqueous mixture in a form for parenteral administration and wherein said insulinotropic peptide or peptides are contained in a second aqueous mixture or solid or gel tab or sustained release matrix [of one or more insulinotropic peptides at a standardized concentration and in a form for parenteral administration].

 Please add new claims 32-50 as follows:

- 32. The method of claim 1, wherein said patient is non-diabetic.
33. The method of claim 1, wherein said insulintropic peptide or peptides is GLP-1, GLP-1 (7-34), GLP-1(7-35), GLP-1 (7-36), GLP (7-37), the deletion sequences thereof, the natural and non-natural amino acid residue substitutes thereof, the C-terminus carboxamides thereof, the C-terminus esters thereof, the D-terminus ketones thereof, the N-terminus modifications thereof or any mixture thereof.
34. The method of claim 1, wherein said insulintropic peptide or peptides is GLP-1 (7-36) amide.
-  35. The method of claim 1, wherein said nutrient and said insulintropic peptide or peptides are administered intravenously, either together or separately.
36. The composition of claim 26, wherein said insulintropic peptide or peptides is GLP-1, GLP-1 (7-34), GLP-1(7-35), GLP-1 (7-36), GLP (7-37), the deletion sequences thereof, the natural and non-natural amino acid residue substitutes thereof, the C-terminus carboxamides thereof, the C-terminus esters thereof, the D-terminus ketones thereof, the N-terminus modifications thereof or any mixture thereof.
37. The composition of claim 26, wherein said insulintropic peptide or peptides is GLP-1 (7-36) amide.
38. The composition of claim 26, wherein said nutrients are in a first aqueous mixture in a form suitable for parenteral administration and said insulintropic peptide or peptides is in a second aqueous mixture or solid or gel tab or sustained release matrix in a form suitable for parenteral administration.

39. The composition of claim 26, wherein said nutrient and said insulintropic peptide or peptides are, either together or separately in a form suitable for intravenous administration.
40. A method for non-alimentary nutrition comprising administering by a parenteral route to a patient in need of parenteral nutrition one or more insulintropic peptides.
41. A method of enhancing metabolic disposal of nutrients, comprising administering by a parenteral route to a non-diabetic patient in need of enhancing metabolic disposal of nutrients a nutrient composition comprising one or more nutrients or any combination thereof and one or more insulintropic peptide or peptides, wherein said peptide or peptides is GLP-1, GLP-1 (7-34), GLP-1(7-35), GLP-1 (7-36), GLP (7-37), the deletion sequences thereof, the natural and non-natural amino acid residue substitutes thereof, the C-terminus carboxamides thereof, the C-terminus esters thereof, the D-terminus ketones thereof, the N-terminus modifications thereof or any mixture thereof.
42. A method of enhancing metabolic disposal of nutrients, comprising administering by a parenteral route to a patient with a disturbed glucose metabolism, a surgery patient, a comatose patient, a patient in shock, a patient with gastrointestinal disease, a patient with digestive hormone disease, an obese patient, an atherosclerotic patient, a patient with vascular disease, a patient with gestational diabetes, a patient with liver disease, a patient with liver cirrhosis, a patient with glucorticoid excess, a patient with Cushings disease, a patient with activated counterregulatory hormones that occur after trauma or a disease, a patient with hypertriglyceridemia, or a patient with chronic pancreatitis, a nutrient composition comprising one or more nutrients or any combination thereof and one or more insulintropic peptides.
43. The method of claim 41, wherein said insulintropic peptide or peptides is GLP-1 (7-36) amide.

Sub C3 44. A method of enhancing metabolic disposal of nutrients, comprising administering by a parenteral route to a patient in need of enhancing metabolic disposal of nutrients a nutrient composition comprising glucose and one or more insulintropic peptide or peptides, wherein said insulintropic peptide or peptides is GLP-1, GLP-1 (7-34), GLP-1(7-35), GLP-1 (7-36), GLP (7-37), the deletion sequences thereof, the natural and non-natural amino acid residue substitutes thereof, the C-terminus carboxamides thereof, the C-terminus esters thereof, the D-terminus ketones thereof, the N-terminus modifications thereof or any mixture thereof.

45. The method of claim 1, wherein said insulintropic peptide or peptides are an incretin.

C 46. A method of treating hyperglycemia, comprising administering by a parenteral route to a hyperglycemic patient ^{a nutritively effective amount of} glucose, fructose, xylitol or any combination thereof and one or more insulintropic peptides.

Sub C4 47. The method of claim 2, wherein the carbohydrate is a glucose, fructose, galactose, xylitol, mannitol, sorbitol, a derivative of any of said carbohydrates, or any combination thereof.

48. The method of claim 1 wherein said nutrient is one or more amino acids, lipids, free fatty acids, mono- or diglycerides or glycerol, a derivative of any of said nutrients, or any combination thereof.

49. The method of claim 2, wherein said carbohydrate is a pyruvate.

50. The method of claim 2, wherein said carbohydrate is a lactate.--